Latest Videos

Senior group leader Simon Boulton from the Francis Crick Institute talks to Adam Blain, a lawyer and writer living with brain cancer, about how DNA damage plays a role in cancer.

Since many cancers don’t have symptoms early on, they may go unnoticed until they are at an advanced stage. But that is changing, thanks to a newer, non-invasive tool.

In this Teach Me in 10, Professor Ophir explains the different narratives often used to communicate science and what impact these narratives can have on the general public's perception of scientific research. He also provides useful tips and tricks on how to communicate science effectively.

What are organoids? Where do they come from? And how can organoids be used to help us understand and treat human diseases?

A new study led by Scripps Research scientist Howard Hang, PhD, explains how and why a certain species of bacteria in the digestive tract significantly improves the tumor-fighting ability of approved cancer drugs known as checkpoint inhibitors.

In this Front Row lecture, you’ll learn why specific bacteria in our body are such powerful mediators of health – and find out about breakthrough discoveries that are now on their way to becoming medicines.

It’s summer, and before you head to the beach or pool, you might slather on sunscreen. But is it doing anything beyond preventing a sunburn? Can it really prevent wrinkles and skin cancer?

Since its release in 2011, canSAR has become the largest, public, cancer drug discovery resource in the world. It brings together billions of pieces of experimental data across disciplines – biology, chemistry, pharmacology, structural biology, cell biology – with clinical insights.

The results of the OlympiA clinical trial, involving ICR researchers, shows giving the drug olaparib for one year to breast cancer patients with inherited BRCA mutations, after they have completed initial treatment, reduced the chance of their breast cancer returning. Professor Andrew Tutt, Head of Breast Cancer Research at the ICR, explains more.

Cancer can affect everybody, but not equally. Certain people, whether because of their gender, race, education or socioeconomic status see worse outcomes from cancer. Access to cancer screening can differ, as well as the quality of patients’ lives after treatment.